编辑精选——严重下肢缺血旁路与血管成形术(BASIL)前瞻性队列研究及BASIL-2随机对照试验的推广性
单中心前瞻性队列研究纳入471例慢性肢体威胁性缺血(CLTI)患者,评估BASIL-2随机对照试验在整体CLTI人群中的代表性。仅95/471(20%)患者接受膝下血运重建(16%在试验外,4%在试验内),多数患者因解剖和技术等因素不适合随机化。BASIL-2结果应在此背景下解读。
要点
- 471例CLTI患者中仅95/471(20%)接受膝下血运重建,其中16%在BASIL-2试验外、4%在试验内。
- 238例需腹股沟下血运重建的患者中,75例(32%)在BASIL-2外接受膝下旁路(39例)或膝下最佳血管内治疗(36例)。
- 多数CLTI患者因解剖和技术等多种原因被认为不适合随机化入BASIL-2。
核心结论
- 需要膝下血运重建并随后随机入BASIL-2的CLTI患者仅占整体CLTI人群的一小部分。
- 由于多种患者、肢体、解剖和操作原因,本队列中多数患者被认为不适合随机化入BASIL-2。
- BASIL-2的结果应在此背景下解读。
研究设计与样本
- 观察性、单中心前瞻性队列研究,使用BASIL-2试验病例报告表记录471例连续入组的CLTI患者。
- 研究于2014年6月24日至2018年7月31日在一家学术血管中心进行,随访数据截尾于2022年12月14日。
- 获得伦理批准,所有患者提供充分知情书面同意。
主要发现
- 238例需要腹股沟下血运重建的患者中,75例(32%)在BASIL-2外接受膝下旁路(39例)或膝下最佳血管内治疗(36例)。
- 17例患者初始随机入BASIL-2;另有3例初始未接受膝下血运重建的患者后来随机入BASIL-2。
- 95/471(20%)患者接受膝下血运重建(16%在试验外,4%在试验内)。
- BASIL-2外膝下旁路与膝下最佳血管内治疗之间的无截肢生存、总生存和保肢差异因样本量小未进行假设检验。
- 未随机入试验的原因众多,常为解剖和技术方面的考虑。
局限性
- BASIL-2外膝下旁路与膝下最佳血管内治疗之间的无截肢生存、总生存和保肢差异因样本量小未进行假设检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Bypass versus Angioplasty in Severe Ischaemia of the Leg-2 (BASIL-2) randomised controlled trial has shown that, for patients with chronic limb threatening ischaemia (CLTI) who require an infrapopliteal (IP) revascularisation a vein bypass (VB) first revascularisation strategy led to a 35% increased risk of major amputation or death when compared with a best endovascular treatment (BET) first revascularisation strategy. The study aims are to place the BASIL-2 trial within the context of the CLTI patient population as a whole and to investigate the generalisability of the BASIL-2 outcome data. METHODS: This was an observational, single centre prospective cohort study. Between 24 June 2014 and 31 July 2018, the BASIL Prospective Cohort Study (PCS) was performed which used BASIL-2 trial case record forms to document the characteristics, initial and subsequent management, and outcomes of 471 consecutive CLTI patients admitted to an academic vascular centre. Ethical approval was obtained, and all patients provided fully informed written consent. Follow up data were censored on 14 December 2022. RESULTS: Of the 238 patients who required an infrainguinal revascularisation, 75 (32%) had either IP bypass (39 patients) or IP BET (36 patients) outside BASIL-2. Seventeen patients were initially randomised to BASIL-2. A further three patients who did not have an IP revascularisation as their initial management were later randomised in BASIL-2. Therefore, 95/471 (20%) of patients had IP revascularisation (16% outside, 4% inside BASIL-2). Differences in amputation free survival, overall survival, and limb salvage between IP bypass and IP BET performed outside BASIL-2 were not subject to hypothesis testing due to the small sample size. Reasons for non-randomisation into the trial were numerous, but often due to anatomical and technical considerations. CONCLUSION: CLTI patients who required an IP revascularisation procedure and were subsequently randomised into BASIL-2 accounted for a small subset of the CLTI population as a whole. For a wide range of patient, limb, anatomical and operational reasons, most patients in this cohort were deemed unsuitable for randomisation in BASIL-2. The results of BASIL-2 should be interpreted in this context.
引用
- Popplewell MA, Meecham L, Davies HOB, et al. Editor's Choice - Bypass versus Angioplasty for Severe Ischaemia of the Leg (BASIL) Prospective Cohort Study and the Generalisability of the BASIL-2 Randomised Controlled Trial. Eur J Vasc Endovasc Surg. 2023. PMID: 37778500. doi:10.1016/j.ejvs.2023.09.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。